Heron Therapeutics, Inc. (HRTX): Price and Financial Metrics
HRTX Price/Volume Stats
Current price | $1.27 | 52-week high | $3.41 |
Prev. close | $1.30 | 52-week low | $0.50 |
Day low | $1.26 | Volume | 915,801 |
Day high | $1.33 | Avg. volume | 2,333,928 |
50-day MA | $0.88 | Dividend yield | N/A |
200-day MA | $1.54 | Market Cap | 189.84M |
HRTX Stock Price Chart Interactive Chart >
HRTX POWR Grades
- Value is the dimension where HRTX ranks best; there it ranks ahead of 74.3% of US stocks.
- The strongest trend for HRTX is in Quality, which has been heading down over the past 177 days.
- HRTX's current lowest rank is in the Sentiment metric (where it is better than 6.66% of US stocks).
HRTX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for HRTX is -3 -- better than merely 3.84% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -64.33 for HERON THERAPEUTICS INC; that's greater than it is for just 0.51% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for HRTX comes in at -91.68% -- higher than that of merely 6.44% of stocks in our set.
- Stocks that are quantitatively similar to HRTX, based on their financial statements, market capitalization, and price volatility, are CASA, NSTG, MTD, SOUN, and GOGO.
- Visit HRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.herontx.com.
HRTX Valuation Summary
- In comparison to the median Healthcare stock, HRTX's price/sales ratio is 75% lower, now standing at 0.9.
- HRTX's price/sales ratio has moved down 7.9 over the prior 243 months.
Below are key valuation metrics over time for HRTX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
HRTX | 2023-11-03 | 0.9 | -2.7 | -0.8 | -1.8 |
HRTX | 2023-11-02 | 0.8 | -2.4 | -0.7 | -1.7 |
HRTX | 2023-11-01 | 0.8 | -2.3 | -0.6 | -1.7 |
HRTX | 2023-10-31 | 0.8 | -2.3 | -0.7 | -1.7 |
HRTX | 2023-10-30 | 0.8 | -2.3 | -0.6 | -1.7 |
HRTX | 2023-10-27 | 0.7 | -2.2 | -0.6 | -1.7 |
HRTX Growth Metrics
- The 4 year revenue growth rate now stands at 2745.98%.
- The 2 year net cashflow from operations growth rate now stands at -89.28%.
- The 5 year net cashflow from operations growth rate now stands at 28.78%.

The table below shows HRTX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 98.299 | -154.636 | -216.801 |
2022-06-30 | 94.972 | -170.736 | -227.301 |
2022-03-31 | 89.785 | -205.355 | -231.957 |
2021-12-31 | 86.346 | -203.354 | -220.683 |
2021-09-30 | 86.296 | -210.65 | -228.318 |
2021-06-30 | 83.031 | -199.538 | -234.138 |
HRTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HRTX has a Quality Grade of D, ranking ahead of 9.05% of graded US stocks.
- HRTX's asset turnover comes in at 0.243 -- ranking 181st of 682 Pharmaceutical Products stocks.
- IBIO, COLL, and PTGX are the stocks whose asset turnover ratios are most correlated with HRTX.
The table below shows HRTX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.243 | 0.485 | -0.993 |
2021-06-30 | 0.228 | 0.515 | -1.093 |
2021-03-31 | 0.224 | 0.582 | -1.080 |
2020-12-31 | 0.214 | 0.592 | -0.933 |
2020-09-30 | 0.227 | 0.586 | -0.779 |
2020-06-30 | 0.277 | 0.581 | -0.676 |
HRTX Price Target
For more insight on analysts targets of HRTX, see our HRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $33.00 | Average Broker Recommendation | 1.42 (Moderate Buy) |
Heron Therapeutics, Inc. (HRTX) Company Bio
Heron Therapeutics is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. The company was founded in 1983 and is based in Redwood City, CA.
Latest HRTX News From Around the Web
Below are the latest news stories about HERON THERAPEUTICS INC that investors may wish to consider to help them evaluate HRTX as an investment opportunity.
CEO & Director of Heron Therapeutics Craig Collard Buys 411% More SharesInvestors who take an interest in Heron Therapeutics, Inc. ( NASDAQ:HRTX ) should definitely note that the CEO... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! |
Heron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024Strategic Cost Reductions and Product Sales Growth Propel Optimism for Profitability |
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call TranscriptHeron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript November 14, 2023 Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.31. Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q3 2023 Earnings Conference Call. As a reminder, this conference is being recorded. […] |
Q3 2023 Heron Therapeutics Inc Earnings CallQ3 2023 Heron Therapeutics Inc Earnings Call |
HRTX Price Returns
1-mo | 99.40% |
3-mo | -19.11% |
6-mo | 13.39% |
1-year | -53.14% |
3-year | -92.67% |
5-year | -95.58% |
YTD | -49.20% |
2022 | -72.62% |
2021 | -56.86% |
2020 | -9.94% |
2019 | -9.41% |
2018 | 43.31% |
Continue Researching HRTX
Here are a few links from around the web to help you further your research on Heron Therapeutics Inc's stock as an investment opportunity:Heron Therapeutics Inc (HRTX) Stock Price | Nasdaq
Heron Therapeutics Inc (HRTX) Stock Quote, History and News - Yahoo Finance
Heron Therapeutics Inc (HRTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...